Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. Bionure has outsourced the development of part of its portfolio to an investee company and is managing the rest of its portfolio internally.
Our lead candidate BN201 is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and has been licensed to Oculis. The product is now in clinical Phase 2 in France.
With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Carrer De Sant Joan De Malta 145, Local 1,spain
- Phone
- 650-690-4701
- in****@****ure.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bionure.com
- Keywords
- neuroprotection, remyelination, rare diseases, acute optic neuritis, neuromyelitis optica, multiple sclerosis, ophthalmology, rnatherapeutics.
- HQ
- Barcelona, Catalunya
Bionure Questions
Bionure's helpline number is 650-690-4701
Bionure's website is bionure.com
Bionure's LinkedIn profile is https://es.linkedin.com/company/bionure
Bionure has
8 employees.
View email and phone details for 8
employees at Bionure.
Bionure's industry is
Biotechnology Research
Bionure's top competitors are
Becytes Biotechnologies,
Sylentis,
Bioingenium, S.l.,
Aelix Therapeutics,
Lipotrue,
Vytrus Biotech,
Ona Therapeutics,
Splicebio,
Sequentia Biotech,
Oryzon Genomics Sa.
Bionure's support email address is info@bionure.com
Bionure's categories are Biotechnology Research
Bionure's founding year is 2009
